中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
EVALUATION AND ANAL YSIS OF DRUG-USE IN HOSPITALS OF CHINA
2014年
10期
870-872
,共3页
卢志文%卢光%黄树明%黄宪平%黄振
盧誌文%盧光%黃樹明%黃憲平%黃振
로지문%로광%황수명%황헌평%황진
恶性胸腹水%热灌注化疗%顺铂
噁性胸腹水%熱灌註化療%順鉑
악성흉복수%열관주화료%순박
Malignant pleural effusion or ascites%Hyperthermic perfusion chemotherapy%Cisplatin
目的:观察体外循环热灌注化疗治疗恶性胸腹水的疗效及不良反应。方法:选择恶性胸腹水患者100例,按照随机数字表法分为治疗组及对照组。治疗组患者50例,采用HGGZ-102体腔循环热化疗系统行体腔热疗,腔内温度达41~43℃,给予顺铂50 mg、地塞米松10 mg注入体腔,体腔循环持续60 min;对照组患者50例,给予体腔注入顺铂50 mg。2组患者均进行1周2次的治疗,疗程为2周。结果:治疗组患者总有效率为76?0%(38/50);对照组为46?0%(23/50),治疗组明显优于对照组( P<0?05);2组不良反应发生率相当。结论:体腔循环灌注热化疗治疗恶性胸腹水疗效好,不良反应可以耐受。
目的:觀察體外循環熱灌註化療治療噁性胸腹水的療效及不良反應。方法:選擇噁性胸腹水患者100例,按照隨機數字錶法分為治療組及對照組。治療組患者50例,採用HGGZ-102體腔循環熱化療繫統行體腔熱療,腔內溫度達41~43℃,給予順鉑50 mg、地塞米鬆10 mg註入體腔,體腔循環持續60 min;對照組患者50例,給予體腔註入順鉑50 mg。2組患者均進行1週2次的治療,療程為2週。結果:治療組患者總有效率為76?0%(38/50);對照組為46?0%(23/50),治療組明顯優于對照組( P<0?05);2組不良反應髮生率相噹。結論:體腔循環灌註熱化療治療噁性胸腹水療效好,不良反應可以耐受。
목적:관찰체외순배열관주화료치료악성흉복수적료효급불량반응。방법:선택악성흉복수환자100례,안조수궤수자표법분위치료조급대조조。치료조환자50례,채용HGGZ-102체강순배열화료계통행체강열료,강내온도체41~43℃,급여순박50 mg、지새미송10 mg주입체강,체강순배지속60 min;대조조환자50례,급여체강주입순박50 mg。2조환자균진행1주2차적치료,료정위2주。결과:치료조환자총유효솔위76?0%(38/50);대조조위46?0%(23/50),치료조명현우우대조조( P<0?05);2조불량반응발생솔상당。결론:체강순배관주열화료치료악성흉복수료효호,불량반응가이내수。
OBJECTIVE:To evaluate the efficacy and side effects of extracorporeal circulation hyperthermic perfusion chemotherapy for malignant pleural effusion or ascites. METHODS:100 cases of malignant pleural effusion or ascites were randomized to either treatment group or control group of 50 cases each. The treatment group received thermotherapy using HGGZ-102 body cavity circulating thermochemotherapy system with intra-cavity maintained at 41-43 ℃ circulation maintained for 60 min and into the cavity cisplatin ( 50 mg ) and dexamethasone ( 10 mg ) were injected;while the control group were injected with cisplatin(50 mg) via body cavity. The medications were given twice a week for two consecutive weeks. RESULTS:The response rate in the treatment group was significantly higher than in the control group [ 76?0%( 38/50 ) vs. 46?0%( 23/50 ); P <0?05 ); there was no statistically significant difference between the two groups in terms of the incidence of adverse reactions. CONCLUSIONS: Body cavity circumfusion thermochemotherapy is effective for malignant pleural effusion or ascites with tolerable adverse reactions.